{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031420","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.218911+00:00","generated_at":"2026-06-08T04:56:51.841711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Atossa Q3 2023: cash $94M; two Phase 2 trials 80% enrolled; net loss details","bullets":["Cash and cash equivalents $94.0M as of Sept 30, 2023.","Two Phase 2 trials (Karisma-Endoxifen, I-SPY 2) at 80% enrollment; data expected H2 2024.","R&D expense $4.5M in Q3 2023, down 13% YoY; G&A $3.0M, flat YoY.","Interest income $1.3M in Q3 2023 vs $0.2M in Q3 2022 due to higher rates and balance.","Jonathan Finn appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031420","json":"https://secwatch.observer/filing/0001437749-23-031420.json","markdown":"https://secwatch.observer/filing/0001437749-23-031420.md","text":"https://secwatch.observer/filing/0001437749-23-031420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/0001437749-23-031420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/atos20231106c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:56:51.841711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37c76a3e1ae385031f4ce1aa943a82ff340a25c5","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2023 financial results and a Company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/0001437749-23-031420-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}